BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AZD0120 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of AZD0120\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07350837-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:AZD0120: Phase 1 readout est. (NCT07350837)
DESCRIPTION:AZD0120\, phase 1.\nStudy: CAR-T Therapy Targeting CD19 and BCM
 A in Highly Sensitized Kidney Transplant Participants\nEstimated primary c
 ompletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07350837
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303790-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270120
DTEND;VALUE=DATE:20270121
SUMMARY:AZD0120: Phase 1 readout est. (NCT07303790)
DESCRIPTION:AZD0120\, phase 1\, Multiple Sclerosis.\nStudy: This is an Earl
 y Exploratory Study to Assess the Tolerability and Safety of GC012F in Pat
 ients With Multiple Sclerosis\nEstimated primary completion: 20 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07303790
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06530849-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT06530849)
DESCRIPTION:AZD0120\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy of GC012F Injection in Subjects With Refractory Systemic Lupus Erythe
 matosus\nEstimated primary completion: 1 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06530849
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06759948-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:AZD0120: Phase 1 readout est. (NCT06759948)
DESCRIPTION:AZD0120\, phase 1.\nStudy: An Early Exploratory Clinical Study 
 of GC012F Injection in the Treatment of Refractory Generalized Myasthenia 
 Gravis\nEstimated primary completion: 13 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06759948
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07058298-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270213
DTEND;VALUE=DATE:20270214
SUMMARY:AZD0120: Phase 1 readout est. (NCT07058298)
DESCRIPTION:AZD0120\, phase 1.\nStudy: GC012F Injection in the Treatment of
  Refractory Generalized Myasthenia Gravis(24103)\nEstimated primary comple
 tion: 13 February 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07058298
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07072884-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:AZD0120: Phase 1 readout est. (NCT07072884)
DESCRIPTION:AZD0120\, phase 1.\nStudy: GC012F in Patients With Autoimmune D
 iseases\nEstimated primary completion: 31 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07072884
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07086404-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:AZD0120: Phase 1 readout est. (NCT07086404)
DESCRIPTION:AZD0120\, phase 1.\nStudy: GC012F Injection in Refractory Idiop
 athic Inflammatory Myopathy\nEstimated primary completion: 15 September 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07086404
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05850234-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT05850234)
DESCRIPTION:AZD0120\, phase 1/2\, Multiple Myeloma.\nStudy: AZD0120 in Rela
 psed/Refractory Multiple Myeloma (DURGA-1)\nEstimated primary completion: 
 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd01
 20#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5850234
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07295847-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280222
DTEND;VALUE=DATE:20280223
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT07295847)
DESCRIPTION:AZD0120\, phase 1/2\, Rheumatoid Arthritis.\nStudy: A Study of 
 AZD0120 in Autoimmune Diseases\nEstimated primary completion: 22 February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07295847
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073547-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280526
DTEND;VALUE=DATE:20280527
SUMMARY:AZD0120: Phase 1 readout est. (NCT07073547)
DESCRIPTION:AZD0120\, phase 1\, Multiple Myeloma.\nStudy: A Phase I\, Open-
 label\, Multicenter Study to Evaluate the Safety\, Tolerability\, Cellular
  Kinetics\, Immunogenicity\, Pharmacodynamics\, and Preliminary Efficacy o
 f AZD0120 in Participants With Multiple Myeloma (DURGA-2)\nEstimated prima
 ry completion: 26 May 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07073547
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391657-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280614
DTEND;VALUE=DATE:20280615
SUMMARY:AZD0120: Phase 3 readout est. (NCT07391657)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: A Study Comparing
  AZD0120\, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) 
 and CD19\, Versus Standard Regimens in Participants With Relapsed Refracto
 ry Multiple Myeloma (DURGA-4)\nEstimated primary completion: 14 June 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07391657
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05858684-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20280810
DTEND;VALUE=DATE:20280811
SUMMARY:AZD0120: Phase 1 readout est. (NCT05858684)
DESCRIPTION:AZD0120\, phase 1\, Systemic Lupus Erythematosus.\nStudy: Dual 
 Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (S
 LE) Patients\nEstimated primary completion: 10 August 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05858684
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07735637-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281102
DTEND;VALUE=DATE:20281103
SUMMARY:AZD0120: Phase 3 readout est. (NCT07735637)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: A Phase III\, Mul
 ticentre Study to Evaluate Consolidation Treatment With AZD0120 Compared W
 ith ASCT\, in Participants With Newly Diagnosed Multiple Myeloma Who Are T
 ransplant Eligible (DURGA-6).\nEstimated primary completion: 2 November 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07735637
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07250269-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:AZD0120: Phase 1 readout est. (NCT07250269)
DESCRIPTION:AZD0120\, phase 1.\nStudy: Study of GC012F\, CAR-T Therapy Targ
 eting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL
  Amyloidosis\nEstimated primary completion: 24 November 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07250269
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07224373-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20281212
DTEND;VALUE=DATE:20281213
SUMMARY:AZD0120: Phase 1 readout est. (NCT07224373)
DESCRIPTION:AZD0120\, phase 1\, Multiple Sclerosis.\nStudy: An Open-label S
 tudy of AZD0120 in Adults With Multiple Sclerosis\nEstimated primary compl
 etion: 12 December 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07224373
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07764978-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290111
DTEND;VALUE=DATE:20290112
SUMMARY:AZD0120: Phase 3 readout est. (NCT07764978)
DESCRIPTION:AZD0120\, phase 3\, Multiple Myeloma.\nStudy: Study of AZD0120 
 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT\nEstimated primary
  completion: 11 January 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/azd0120#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07764978
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06897930-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT06897930)
DESCRIPTION:AZD0120\, phase 1/2\, Systemic Lupus Erythematosus.\nStudy: A S
 tudy to Investigate the Safety\, Tolerability\, and Efficacy of AZD0120 in
  Adults With Refractory SLE\nEstimated primary completion: 1 May 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06897930
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081646-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20290815
DTEND;VALUE=DATE:20290816
SUMMARY:AZD0120: Phase 1/2 readout est. (NCT07081646)
DESCRIPTION:AZD0120\, phase 1/2.\nStudy: A Phase 1b/2 Study of CAR T Cell T
 herapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory
  AL Amyloidosis.\nEstimated primary completion: 15 August 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/azd0120#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07081646
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07790575-3183@assetmemo.bio
DTSTAMP:20261121T004051Z
DTSTART;VALUE=DATE:20410731
DTEND;VALUE=DATE:20410801
SUMMARY:AZD0120: Phase 1 readout est. (NCT07790575)
DESCRIPTION:AZD0120\, phase 1.\nStudy: Autoimmune Cytopenia Elimination by 
 Chimeric Antigen Receptor T-cell Therapy\nEstimated primary completion: Ju
 ly 2041. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/azd0120#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07790575
URL:https://assetmemo.bio/drug/azd0120#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
